Over the past decade, a new era of innovation has pushed the frontiers of science, leading to remarkable progress for patients with a wide range of rare diseases. Collectively, these diseases impact 30 million Americans and 400 million people worldwide. Despite the challenges, throughout the last decade, America's biopharmaceutical researcher companies have made significant progress in the development of groundbreaking therapies.